RAUWILOID Drug Patent Profile
✉ Email this page to a colleague
When do Rauwiloid patents expire, and when can generic versions of Rauwiloid launch?
Rauwiloid is a drug marketed by 3M and is included in one NDA.
The generic ingredient in RAUWILOID is alseroxylon. Additional details are available on the alseroxylon profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RAUWILOID?
- What are the global sales for RAUWILOID?
- What is Average Wholesale Price for RAUWILOID?
Summary for RAUWILOID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 17 |
| Patent Applications: | 3,490 |
| DailyMed Link: | RAUWILOID at DailyMed |
US Patents and Regulatory Information for RAUWILOID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3m | RAUWILOID | alseroxylon | TABLET;ORAL | 008867-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
